121 related articles for article (PubMed ID: 34497200)
41. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui CH
Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
[TBL] [Abstract][Full Text] [Related]
42. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract][Full Text] [Related]
43. [Clinical and laboratorial analysis for 15 adult cases of mixed phenotypic acute leukemia with Ph chromosome and/or positive BCR-ABL].
Yan LZ; Chen SN; Ping NN; Wang QR; Liu H; Ding ZX; Zhu MQ; Liang JY; Liu DD; Cen JN; Pan JL; Qiu HY; Sun AN; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1116-20. PubMed ID: 24156417
[TBL] [Abstract][Full Text] [Related]
44. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317
[TBL] [Abstract][Full Text] [Related]
45. Ph-like acute lymphoblastic leukemia.
Tran TH; Loh ML
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):561-566. PubMed ID: 27913529
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
[TBL] [Abstract][Full Text] [Related]
47. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
49. Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia?
Tasian SK; Peters C
Lancet Haematol; 2020 Dec; 7(12):e858-e859. PubMed ID: 33242441
[No Abstract] [Full Text] [Related]
50. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
51. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.
Roberts KG; Yang YL; Payne-Turner D; Lin W; Files JK; Dickerson K; Gu Z; Taunton J; Janke LJ; Chen T; Loh ML; Hunger SP; Mullighan CG
Blood Adv; 2017 Sep; 1(20):1657-1671. PubMed ID: 29296813
[TBL] [Abstract][Full Text] [Related]
52. Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion.
Yano M; Imamura T; Asai D; Kiyokawa N; Nakabayashi K; Matsumoto K; Deguchi T; Hashii Y; Honda YK; Hasegawa D; Sasahara Y; Ishii M; Kosaka Y; Kato K; Shima M; Hori H; Yumura-Yagi K; Hara J; Oda M; Horibe K; Ichikawa H; Sato A
Br J Haematol; 2015 Dec; 171(5):813-7. PubMed ID: 26404892
[TBL] [Abstract][Full Text] [Related]
53. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
54. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S
Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401
[TBL] [Abstract][Full Text] [Related]
55. Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.
Lukes J; Potuckova E; Sramkova L; Stary J; Starkova J; Trka J; Votava F; Zuna J; Zaliova M
Genes Chromosomes Cancer; 2018 Sep; 57(9):471-477. PubMed ID: 29726059
[TBL] [Abstract][Full Text] [Related]
56. BCL6 inhibition ameliorates resistance to ruxolitinib in
Tsuzuki S; Yasuda T; Goto H; Maeda N; Akahane K; Inukai T; Yamamoto H; Karnan S; Ota A; Hyodo T; Konishi H; Hosokawa Y; Kiyoi H; Hayakawa F
Haematologica; 2023 Feb; 108(2):394-408. PubMed ID: 36005560
[TBL] [Abstract][Full Text] [Related]
57. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
58. Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.
Vesely C; Frech C; Eckert C; Cario G; Mecklenbräuker A; Zur Stadt U; Nebral K; Kraler F; Fischer S; Attarbaschi A; Schuster M; Bock C; Cavé H; von Stackelberg A; Schrappe M; Horstmann MA; Mann G; Haas OA; Panzer-Grümayer R
Leukemia; 2017 Jul; 31(7):1491-1501. PubMed ID: 27899802
[TBL] [Abstract][Full Text] [Related]
59. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
60. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]